A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2001
11/27/2001	US6322493 Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds
11/27/2001	CA2184551C Iron dextran formulations
11/27/2001	CA2079685C Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
11/26/2001	CA2346163A1 Complex for transferring an anionic substance of interest into a cell
11/22/2001	WO2001088116A2 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods
11/22/2001	WO2001088105A2 Production of dendritic cells from bone-marrow stem cells
11/22/2001	WO2001088019A1 Material based on biodegradable polymers and method for preparing same
11/22/2001	WO2001088017A1 Polypeptide derivatives and nucleic acid carriers containing the same
11/22/2001	WO2001087982A2 Immunotoxin fusion proteins and means for expression thereof
11/22/2001	WO2001087935A2 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
11/22/2001	WO2001087934A2 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides
11/22/2001	WO2001087841A1 Novel polymorph v of torasemide
11/22/2001	WO2001087376A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/22/2001	WO2001087374A1 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087373A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087348A2 Multifunctional nanodevice platform
11/22/2001	WO2001087346A2 Dendritic cells loaded with toxic substances
11/22/2001	WO2001087345A1 Stable polymeric micelle-type drug composition and method for the preparation thereof
11/22/2001	WO2001087344A1 Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid
11/22/2001	WO2001087342A2 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087329A1 Liquid pharmaceutical composition containing an erythropoietin derivate
11/22/2001	WO2001087322A2 Peptide pharmaceutical formulations
11/22/2001	WO2001087310A1 Process for reducing antibody response against xenografts
11/22/2001	WO2001087303A1 Aqueous liquid preparation
11/22/2001	WO2001087301A1 Methods for treatment of inflammatory diseases
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087298A1 Water-based liquid preparation
11/22/2001	WO2001087289A2 Propofol for treatment of sepsis
11/22/2001	WO2001087278A1 Insulin formulation for inhalation
11/22/2001	WO2001087276A1 Hydrogel composition for transdermal drug delivery
11/22/2001	WO2001087272A2 Encapsulating a toxic core within a non-toxic region in an oral dosage form
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087266A1 Stabilized aqueous suspensions for parenteral use
11/22/2001	WO2001087265A2 Pharmaceutical form of administration for peptides, methods for its production and use
11/22/2001	WO2001087264A2 Rapidly disintegrating solid oral dosage form
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087262A2 Stabilized steroidal suspension
11/22/2001	WO2001087255A1 External application for enhancing the skin permeability of the active components therein
11/22/2001	WO2001087254A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	WO2001087232A2 Allantoin-containing skin cream
11/22/2001	WO2001087203A1 Stabilized budesonide solution and method for making same
11/22/2001	WO2001087039A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
11/22/2001	WO2001036611A8 Process for the production of a reversibly inactive acidified plasmin composition
11/22/2001	WO2001034792A3 Compositions and methods for the diminution or elimination of various cancers
11/22/2001	WO2001034185A3 Induction of mucosal immunity by vaccination via the skin route
11/22/2001	WO2001034119A3 Inhibitors of crystallization in a solid dispersion
11/22/2001	WO2001000242A3 Polycation-based bioconjugates
11/22/2001	US20010044623 Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
11/22/2001	US20010044584 In vivo delivery methods and compositions
11/22/2001	US20010044583 Gas filled liposomes and their use as ultrasonic contrast agents
11/22/2001	US20010044528 5'-O-alkyl nucleotide, block of phosphodiester-linked 2'-O-alkyl ribonucleotides, a block of phosphorothioate-linked deoxyribonucleotides, and a blocking group for nuclease resistance; lipid-peptoid carrier
11/22/2001	US20010044526 Water soluble polymer backbone such as polyethylene glycol, endcapped with a N-maleimidyl moiety without using a linker; conjugated peptides, proteins, nucleotides and drugs
11/22/2001	US20010044474 Hydrogel-driven layered drug dosage form
11/22/2001	US20010044472 Fluidizing agent, a binder compound, a starch, a disintegrant and a lubricant; free-flowing; tablets
11/22/2001	US20010044460 Ophthalmic compositions for treating ocular hypertension
11/22/2001	US20010044425 Therapeutically effective amount of ferrous ion and a therapeutically effective amount of an ascorbate
11/22/2001	US20010044421 Antimutagenic compositions for treatment and prevention of photodamage to skin
11/22/2001	US20010044419 Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells
11/22/2001	US20010044409 Increase bioavailability of water insoluble drugs by spraying a surfactant-plasticizer/solubilizer solution on a drug-carrier mixture in a fluid bed granulator, and extruding, milling to a powdery mass of solid drug dispersion
11/22/2001	US20010044397 Bleaching enzymes and detergent compositions comprising them
11/22/2001	US20010044026 Placing a hog fuel mat including an ammonium chloride catalyst with flexible non-sticking layers on outside surfaces between screens in a preheated platen press and pressing the mat
11/22/2001	US20010043950 Core of fluvastatin, hydroxypropyl methyl cellulose and optionally other excipients, dosage form is color-stable during storage
11/22/2001	US20010043949 Biodegradable synthetic polymer microparticle, proteinaceous antigen and an enteric polymer which forms a coating layer on the surface of the microparticle; oral delivery of vaccine
11/22/2001	US20010043948 Lipid or other hydrophobic or amphiphilic compound is integrated into a polymeric matrix to alter drug release kinetics; drug released over longer periods of time by altering diffusion of water
11/22/2001	US20010043947 Soft chewable tablets
11/22/2001	US20010043934 Formulations for amylin agonist peptides
11/22/2001	US20010043929 Enhanced circulation effector composition and method
11/22/2001	US20010043908 Liquid oral compositions comprising a calcium compound and an acidulant
11/22/2001	US20010043906 Aerosolizing a solution of aqueous gamma-interferon, a stabilizer and a dispersant by forcing the solution through openings in a plate and delivering the droplets to a patient's respiratory tract; storage stability
11/22/2001	US20010042936 Process for producing solid creatine dosage forms and dosage forms obtainable thereby
11/22/2001	DE10033990A1 Cyclodextrine, die vorzugsweise an ihrer primären Fläche durch Säure- oder Aminfunktionen substituiert sind Cyclodextrins, which are preferably substituted on its primary surface by acid or amine functions
11/22/2001	CA2409746A1 Immunotoxin fusion proteins and means for expression thereof
11/22/2001	CA2409699A1 Novel polymorph v of torasemide
11/22/2001	CA2408870A1 Material based on biodegradable polymers and method for preparing same
11/22/2001	CA2408729A1 Delivery systems for treatment of vascular disease
11/22/2001	CA2408719A1 Antiproliferative drug and delivery device
11/22/2001	CA2408689A1 Allantoin-containing skin cream
11/22/2001	CA2408608A1 Antiinflammatory drug and delivery device
11/22/2001	CA2408383A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	CA2408163A1 Methods for treatment of inflammatory diseases
11/22/2001	CA2407540A1 Propofol for treatment of sepsis
11/22/2001	CA2407254A1 Insulin formulation for inhalation
11/22/2001	CA2407099A1 Aralkyl ester soft drugs
11/22/2001	CA2380423A1 Peptide pharmaceutical formulations
11/21/2001	EP1156118A1 Virus vector
11/21/2001	EP1155702A1 Dds compounds and method for assaying the same
11/21/2001	EP1155701A1 Enteral sorbefacients
11/21/2001	EP1155692A1 Use of Paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
11/21/2001	EP1155691A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155690A2 Anti-angiogenic compositions and method of use
11/21/2001	EP1155689A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155677A2 Methods and compositions for inhibiting free radical polymerization in skin and hair
11/21/2001	EP1155043A1 Stabilized cyclodextrin complexes
11/21/2001	EP1155037A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists therof, and their therapeutic uses
11/21/2001	EP1155035A2 Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof
11/21/2001	EP1154800A2 Dry acid-chitosan complexes
11/21/2001	EP1154799A2 Biotinylated-chemokine antibody complexes
11/21/2001	EP1154798A1 Molecules for the treatment and diagnosis of tumors
11/21/2001	EP1154797A2 Multi-mutant diphtheria toxin vaccines

1 ... 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 ... 1712